| Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in AK Nowak, WJ Lesterhuis, PS Kok, C Brown, BGM Hughes, DJ Karikios, ... The Lancet Oncology 21 (9), 1213-1223, 2020 | 131 | 2020 |
| Immunotherapy‐induced sarcoidosis in patients with melanoma treated with PD‐1 checkpoint inhibitors: case series and immunophenotypic analysis AJ Lomax, HM McGuire, C McNeil, CJ Choi, P Hersey, D Karikios, ... International journal of rheumatic diseases 20 (9), 1277-1285, 2017 | 95 | 2017 |
| Practical considerations for treating patients with cancer in the COVID-19 pandemic E Segelov, C Underhill, H Prenen, C Karapetis, C Jackson, L Nott, T Clay, ... JCO Oncology Practice 16 (8), 467-482, 2020 | 66 | 2020 |
| OA08. 02 DREAM-a phase 2 trial of durvalumab with first line chemotherapy in mesothelioma: final result A Nowak, P Kok, W Lesterhuis, B Hughes, C Brown, S Kao, D Karikios, ... Journal of Thoracic Oncology 13 (10), S338-S339, 2018 | 49 | 2018 |
| Rising cost of anticancer drugs in A ustralia DJ Karikios, D Schofield, G Salkeld, KP Mann, J Trotman, MR Stockler Internal medicine journal 44 (5), 458-463, 2014 | 48 | 2014 |
| Evaluating prognostic factors for sex differences in lung cancer survival: findings from a large Australian cohort XQ Yu, ML Yap, ES Cheng, PJ Ngo, P Vaneckova, D Karikios, K Canfell, ... Journal of Thoracic Oncology 17 (5), 688-699, 2022 | 32 | 2022 |
| DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results. AK Nowak, WJ Lesterhuis, BGM Hughes, C Brown, PS Kok, KJ O'Byrne, ... Journal of Clinical Oncology 36 (15_suppl), 8503-8503, 2018 | 30 | 2018 |
| Metabolic information on staging FDG-PET–CT as a prognostic tool in the evaluation of 97 patients with gastric cancer NA Coupe, D Karikios, S Chong, J Yap, W Ng, N Merrett, M Lin Annals of nuclear medicine 28, 128-135, 2014 | 30 | 2014 |
| Common Sense Oncology: outcomes that matter CM Booth, M Sengar, A Goodman, B Wilson, A Aggarwal, S Berry, ... The Lancet Oncology 24 (8), 833-835, 2023 | 28 | 2023 |
| SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response CR McEvoy, L Koe, DY Choong, HS Leong, H Xu, D Karikios, JD Plew, ... NPJ Precision Oncology 2 (1), 9, 2018 | 28 | 2018 |
| Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians G Chazan, F Franchini, M Alexander, S Banerjee, L Mileshkin, P Blinman, ... ESMO open 5 (6), e001090, 2020 | 22 | 2020 |
| A qualitative study of medical oncologists’ experiences of their profession and workforce sustainability A Broom, WKT Wong, E Kirby, D Sibbritt, D Karikios, R Harrup, Z Lwin PloS one 11 (11), e0166302, 2016 | 18 | 2016 |
| Physician-patient communication of costs and financial burden of cancer and its treatment: a systematic review of clinical guidelines A Agarwal, A Livingstone, DJ Karikios, MR Stockler, PJ Beale, RL Morton BMC cancer 21, 1-10, 2021 | 17 | 2021 |
| Nurse-led supportive care management: a 6-month review of the role of a nurse practitioner in a chemotherapy unit K Cox, D Karikios, JK Roydhouse, K White Australian Health Review 37 (5), 632-635, 2013 | 17 | 2013 |
| Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia DJ Karikios, L Chim, A Martin, A Nagrial, K Howard, G Salkeld, ... Internal medicine journal 47 (4), 400-407, 2017 | 15 | 2017 |
| The Australian medical oncologist workforce survey: the profile and challenges of medical oncology Z Lwin, A Broom, D Sibbritt, K Francis, CS Karapetis, D Karikios, R Harrup Seminars in Oncology 45 (5-6), 284-290, 2018 | 13 | 2018 |
| Retrospective evaluation of the use of Pembrolizumab in malignant mesothelioma in a real-world Australian population T Ahmadzada, WA Cooper, M Holmes, A Mahar, H Westman, AJ Gill, ... JTO Clinical and Research Reports 1 (4), 100075, 2020 | 12 | 2020 |
| Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study K Jenei, AJN Raymakers, A Bayle, K Berger-Thürmel, A Cherla, K Honda, ... The Lancet Oncology 24 (6), 624-635, 2023 | 11 | 2023 |
| Applying utility values in cost-effectiveness analyses of lung cancer screening: a review of methods PJ Ngo, S Cressman, S Behar-Harpaz, DJ Karikios, K Canfell, MF Weber Lung Cancer 166, 122-131, 2022 | 10 | 2022 |
| Lung cancer treatment patterns and factors relating to systemic therapy use in Australia P Ngo, DE Goldsbury, D Karikios, S Yap, ML Yap, S Egger, DL O'Connell, ... Asia‐Pacific Journal of Clinical Oncology 18 (5), e235-e246, 2022 | 9 | 2022 |
